Chemotherapy for Patients with Colorectal Liver Metastases Who Underwent Curative Resection Improves Long-Term Outcomes: Systematic Review and Meta-analysis
- 14 January 2015
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (9) , 3070-3078
Abstract
Hepatic resection is considered the standard of care for patients with resectable colorectal liver metastases (CRLM), but the benefits of using systemic chemotherapy for these patients have not been completely proven. Although systemic chemotherapy is likely to improve recurrence-free survival (RFS), no differences in overall survival (OS) have been demonstrated to date. This study aimed to compare surgery plus systemic chemotherapy, regardless timing of administration, with surgery alone, analyzing long-term outcomes for patients with CRLM who underwent liver resection with curative intent. Systematic review and meta-analysis of studies published from January 1991 to December 2013 were used to compare surgery alone and surgery plus chemotherapy for patients with CRLM who underwent liver resection with curative intent. All randomized clinical trials (RCTs) were included in the study. Selection of high-quality observational comparative studies (OCSs) was based on a validated tool, the Methodological Index for Nonrandomized Studies. Comparison of RFS and OS was performed using a fixed-effects model and the hazard ratio (HR). Concerning OS, 5 studies (3 RCTs and 2 OCSs) comprising 2,475 patients were analyzed, and chemotherapy (1,024 patients) relatively improved OS rates for 23 % of the patients versus surgery alone (HR, 0.77; 95 % confidence interval [CI] 0.67–0.88; p < 0.001). Four studies, totaling 1,592 patients, reported RFS (3 using RCTs and 1 using OCSs), showing that chemotherapy (702 patients) relatively improved RFS for 29 % of the patients (HR, 0.71; 95 % CI 0.61–0.83; p < 0.001). This meta-analysis demonstrated that the use of chemotherapy for patients with CRLM who underwent resection with curative intent is a worthwhile strategy for improving both RFS and OS.Keywords
This publication has 31 references indexed in Scilit:
- Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?Journal of Surgical Oncology, 2011
- The management of resectable and unresectable liver metastases from colorectal cancerCurrent Opinion in Oncology, 2010
- Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver MetastasesAnnals of Surgical Oncology, 2009
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008
- Simultaneous Resections of Colorectal Cancer and Synchronous Liver Metastases: A Multi-institutional AnalysisAnnals of Surgical Oncology, 2007
- Statistical Power of Negative Randomized Controlled Trials Presented at American Society for Clinical Oncology Annual MeetingsJournal of Clinical Oncology, 2007
- Tumor Progression While on ChemotherapyAnnals of Surgery, 2004
- Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver MetastasesAnnals of Surgery, 2004
- Resection of Nonresectable Liver Metastases from Colorectal Cancer After Neoadjuvant ChemotherapyAnnals of Surgery, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986